2005 – 2009   药物制剂  中国药科大学，学士
2009 – 2012   药物化学  中国科学院上海药物研究所，硕士（导师：叶阳 教授）
2012 – 2013   药物化学生物学  清华大学，科研助理（导师：廖学斌 教授）
2013 – 2018   药物化学生物学  科罗拉多大学博尔德分校，博士（导师：尹航 教授）
2018 – 2023   药物化学生物学  耶鲁大学，博士后（导师：Craig Crews 教授）
2023.5 - 至今  药物化学生物学 中国科学院生物与化学交叉研究中心,研究员、课题组长

　　胡振一研究员博士毕业于科罗拉多大学博尔德分校，师从尹航教授；博后师从PROTAC技术的创始人-耶鲁大学的Craig Crews教授（合作导师 Yansheng Liu教授）。胡振一研究员聚焦于药物化学生物学，以自身免疫疾病与癌症为目标，在重要蛋白的小分子抑制剂研发方面积累了丰富的经验：首次通过基于结构的理性设计等方法研发了高效TLR8小分子抑制剂，TLR8抑制剂获得国际、美国和中国专利并转让，已获得中国和美国FDA临床受理，启动了临床试验；首次研发了继PROTAC之后的新一代靶向蛋白磷酸化的双功能小分子抑制剂（PhosTAC），其相较传统激酶抑制剂具有高效精确特异性等优点，PhosTAC作为新的通用型药物开发平台型技术，有广泛应用潜力。胡振一研究员以第一/共一/共同通讯作者在Nature Chemical Biology,Journal of the American Chemical Society,Cell Chemical Biology,ACS Chemical Biology等专业期刊上发表论文7篇，以上工作获得国际同行的高度认可，多次被C&EN、Science Trends、Trends in Pharmacological Sciences 和 Science Daily等期刊和科学媒体报道。

致力于利用化学手段研究和调控生命活动过程。本课题组聚焦于双功能分子（PROTAC，PhosTAC等），以生物功能为目标，以化学合成为手段 （Biology driven,chemistry empowered），调控生命和疾病的发生过程，做生命的工程师。我们的目标是基于双功能分子药物，开发老年痴呆症、癌症等疾病的治疗方法。

1. Hu,Z.#;Chen,P.#;Li,W.;Douglas,T.;Hines,J.;Liu,Y.;Crews,C.;Targeted Dephosphorylation of Tau by Phosphorylation Targeting Chimeras (PhosTACs) as a Therapeutic Modality. Journal of the American Chemical Society. 2023,145,7,4045–4055

2. Zhang,S.#; Hu,Z.#;Tanji,H.;Jiang,S.;Das,N.;Li,J.;Sakaniwa,K.;Jin,J.;Bian,Y.;Ohto,U.;Shimizu,T.;Yin,H.;Inhibition of Toll-like Receptor 8 through stabilization of its resting state. Nature Chemical Biology. 2018,14,58-64 (cover article)

3. Hu,Z.;Tanji,H.;Koo,K.;Chan,J.;Zhang,S.;Candia,A.;Shimizu,T.;Yin,H.;Small-molecule TLR8 antagonists via structure-based rational design. Cell Chemical Biology. 2018,25,1286–1291 (cover article)

4. Hu,Z.;Crews,C.;Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic. Chembiochem. 2022,23 (2),e202100270. 

5. Chen,P. #; Hu,Z. #;An,E.;Okeke,I.;Zheng,S.;Lo,X.;Gong,A.;Jaime-Figueroa,S.;Crews,C.;Modulation of Phosphoprotein Activity by Phosphorylation Targeting Chimeras (PhosTACs). ACS Chemical Biology. 2021,16,12,2808–2815.

6. Hu,Z.;Zhang,T.;Jiang,S.;Yin,H.;Protocol for evaluation and validation of TLR8 antagonists in HEK-Blue cells via secreted embryonic alkaline phosphatase assay. Cell Star Protocols. 2022,3,101061.

7. Samarasinghe,K.;Jaime-Figueroa,S.;Burgess,M.;Nalawansha,D.;Dai,K.; Hu,Z.;Bebenek,A.;Holley,S.;Crews,C.;Targeted degradation of transcription factors by TRAFTACs: TRAnscription Factor TArgeting Chimeras. Cell Chemical Biology. 2021,28(5):648-661 e645.

8. Hany,Z.;Meas,H.;Haug,M.;Beckwith,M.;Louet,C.;Ryan,L.; Hu,Z.;Landskron,J.;Nordbo,S.;Tasken,K,;Yin,H.;Damas,J.;Flo. T.; Sensing of HIV-1 by TLR8 activates human T cells and reverses latency. Nature Communication. 2020 Jan 9;11(1):147

9. Xia,T.; Hu,Z.;Ji,W.;Zhang,S.;Shi,H.;Liu,C.;Pang,B.;Liu,G.;Liao,X.;Synthesis of Withasomnine and Pyrazole derivatives via intramolecular dehydrogenative cyclization,as well as biological evaluation of Withasomnine-based scaffolds. Organic Chemistry Frontiers. 2018,5,850-854 

10. Moen,S.;Ehrnstrom,B.;Kojen,J.;Yurchenko,Beckwith,K.;Afset,J.;Damas,J.;Hu,Z.;Yin,H.;Espevik,T.;Stenvik,J.;Human Toll-like Receptor 8 (TLR8) is an important sensor of pyogenic bacteria,and is attenuated by cell surface TLR signaling. Frontier in Immunology.10:1209.

11. Ehrnstrom,B.;Kojen,J.F.;Moen,S.H.; Hu,Z.;Damas,J.K.,Mollnes,T.E.;Yin,H.;Espevik,T.;Stenvik J.;TLR8 and complement C5 induce cytokine release and thrombin activation in human whole blood challenged with Gram-positive bacteria. Journal of Leukocyte Biology 2020,107,673–683.

12. Chen,H.#; Hu,Z.#;Tang,C.;Quinn,R.;Feng,Y.;Yao,S.;Ye Y.;Dictamins A–C,three unprecedented apotirucallane-type trinortriterpenoids from Dictamnus dasycarpus.Tetrahedron Letters. 2013,5,4150–4153

13. Qi X.;Wang,L.;Zhu,J.; Hu,Z.;Zhang,J.;Self-double-emulsifying drug delivery system (SDEDDS):A new way for oral delivery of drugs with high solubility and low permeability. International Journal of Pharmaceutics. 2011,409,245–251.

# Co-First Author.